EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up for Myelodysplastic Syndromes by Arjan A. van de Loosdrecht, Inga Mandac Smoljanović

Get full text

Management of patients with lower-risk myelodysplastic syndromes by Andrew M. Brunner, Heather A. Leitch, Arjan A. van de Loosdrecht, Nicolas Bonadies

Get full text

6-Sulfo LacNAc (Slan) as a Marker for Non-classical Monocytes by Thomas P. Hofer, Arjan A. van de Loosdrecht, Christiane Stahl-Hennig, Marco A. Cassatella, Loems Ziegler-Heitbrock

Get full text

Durable Responses and Survival in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients Receiving the Allogeneic Leukemia-derived Dendritic Cell Vaccine DCP-001 by Luca L.G. Janssen, Theresia M. Westers, Jeroen Rovers, Peter J.M. Valk, Jacqueline Cloos, Tanja D. de Gruijl, Arjan A. van de Loosdrecht

Get full text

Human Bone Marrow-Derived Myeloid Dendritic Cells Show an Immature Transcriptional and Functional Profile Compared to Their Peripheral Blood Counterparts and Separate from Slan+ No... by Nathalie van Leeuwen-Kerkhoff, Kristina Lundberg, Theresia M. Westers, Shahram Kordasti, Hetty J. Bontkes, Malin Lindstedt, Tanja D. de Gruijl, Arjan A. van de Loosdrecht

Get full text

A Human Cell Line Model for Interferon-α Driven Dendritic Cell Differentiation. by Jurjen M Ruben, Lindy L Visser, Kimberley M Heinhuis, Tom O'Toole, Hetty J Bontkes, Theresia M Westers, Gert J Ossenkoppele, Tanja D de Gruijl, Arjan A van de Loosdrecht

Get full text

Increased prescription rate of anti‐infective agents after diagnosis of myelodysplastic syndromes by Johanne Rozema, Mels Hoogendoorn, Iris Potma, Inge tenSeldam, Nic J. G. M. Veeger, Robby E. Kibbelaar, Arjan A. van deLoosdrecht, Eric N. vanRoon, the HemoBase Population Registry Consortium

Get full text

Prognostic Significance of Measurable Residual Disease Detection by Flow Cytometry in Autologous Stem Cell Apheresis Products in AML by Jesse M. Tettero, Yara Buisman, Lok Lam Ngai, Costa Bachas, Bjorn T. Gjertsen, Angèle Kelder, Arjan A. van de Loosdrecht, Markus G. Manz, Thomas Pabst, Willemijn Scholten, Gert J. Ossenkoppele, Jacqueline Cloos, David C. de Leeuw

Get full text

Immune-based Therapies for Hematological Malignancies: An Update by the EHA SWG on Immunotherapy of Hematological Malignancies by Hermann Einsele, Javier Briones, Fabio Ciceri, Irene García-Cadenas, Fred Falkenburg, Natacha Bolaños, H.M. Mirjam Heemskerk, Roch Houot, Michael Hudecek, Franco Locatelli, Kate Morgan, C. Emma Morris, Michael O’Dwyer, Jordi Sierra Gil, Marcel van den Brink, Arjan A. van de Loosdrecht

Get full text

The EHA Research Roadmap: Immune-based Therapies for Hematological Malignancies by Hermann Einsele, Javier Briones, Fabio Ciceri, Irene García Cadenas, Fred Falkenburg, Natacha Bolaños, H.M. Mirjam Heemskerk, Roch Houot, Michael Hudecek, Franco Locatelli, Kate Morgan, Emma C. Morris, Michael O’Dwyer, Jordi Gil Sierra, Marcel van den Brink, Arjan A. van de Loosdrecht

Get full text

Glycan-Modified Apoptotic Melanoma-Derived Extracellular Vesicles as Antigen Source for Anti-Tumor Vaccination by Sophie K. Horrevorts, Dorian A. Stolk, Rieneke van de Ven, Myrthe Hulst, Bert van Het Hof, Sanne Duinkerken, Marieke H. Heineke, Wenbin Ma, Sophie A. Dusoswa, Rienk Nieuwland, Juan J. Garcia-Vallejo, Arjan A. van de Loosdrecht, Tanja D. de Gruijl, Sandra J. van Vliet, Yvette van Kooyk

Get full text

Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine by Jacobien R. Hilberink, Isabelle A. van Zeventer, Dana A. Chitu, Thomas Pabst, Saskia K. Klein, Georg Stussi, Laimonas Griskevicius, Peter J. M. Valk, Jacqueline Cloos, Arjan A. van de Loosdrecht, Dimitri Breems, Danielle van Lammeren-Venema, Rinske Boersma, Mojca Jongen-Lavrencic, Martin Fehr, Mels Hoogendoorn, Markus G. Manz, Maaike Söhne, Rien van Marwijk Kooy, Dries Deeren, Marjolein W. M. van der Poel, Marie Cecile Legdeur, Lidwine Tick, Yves Chalandon, Emanuele Ammatuna, Sabine Blum, Bob Löwenberg, Gert J. Ossenkoppele, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Swiss Group for Clinical Cancer Research (SAKK), Gerwin Huls

Get full text

The ABNL-MARRO 001 study: a phase 1–2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes by Tamara K. Moyo, Jason H. Mendler, Raphael Itzykson, Ashwin Kishtagari, Eric Solary, Adam C. Seegmiller, Aaron T. Gerds, Gregory D. Ayers, Amy E. Dezern, Aziz Nazha, Peter Valent, Arjan A. van de Loosdrecht, Francesco Onida, Lisa Pleyer, Blanca Xicoy Cirici, Raoul Tibes, Klaus Geissler, Rami S. Komrokji, Jing Zhang, Ulrich Germing, David P. Steensma, Daniel H. Wiseman, Michael Pfeilstöecker, Chiara Elena, Nicholas C. P. Cross, Jean-Jacques Kiladjian, Michael Luebbert, Ruben A. Mesa, Guillermo Montalban-Bravo, Guillermo F. Sanz, Uwe Platzbecker, Mrinal M. Patnaik, Eric Padron, Valeria Santini, Pierre Fenaux, Michael R. Savona, On Behalf of the MDS/MPN International Working Group

Get full text